Shares of Ireland-incorporated generic and OTC drugmaker Perrigo (NYSE: PRGO) soared 17% to $77.90 by late morning on Thursday, having surged as much as 20.4%, after the company revealed it has reached an agreement to divest its Israel Active Pharmaceutical Ingredient business for $110 million in cash, and posted better-than-expected second-quarter 2017 financial results.
SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced that it has signed a definitive agreement to acquire Perrigo API, the active pharmaceutical ingredients (API) business of Perrigo.
As part of the transaction, the parties have agreed to enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The transaction is expected to close during fourth-quarter 2017, before which a new trade name will be selected and announced for the business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze